Abstracts Archive - Page 169 of 2607 - ACR Meeting Abstracts

Abstract Number: 0243 • ACR Convergence 2025
Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain
Carmen Lasa Teja¹, Laura Muñoz-Llopis², Diana Prieto-Peña³, Isla Morante Bolado⁴, José Luis Martín-Varillas⁵, Nerea Paz-Gandiaga⁶ and Ricardo Blanco⁷, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, ⁵Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ⁶Rheumatology, Hospital Comarcal de Laredo, Laredo, Spain., Santander, ⁷Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Systemic autoinflammatory diseases (SAIDs) are rare disorders characterized by recurrent episodes of fever, serositis, gastrointestinal symptoms, arthritis, and/or skin lesions. In adult-onset SAIDs, clinical…
Abstract Number: 0619 • ACR Convergence 2025
Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
Luciana Parente Costa Seguro¹, Andrea Negrini², Sandra G Pasoto³, Nadia E Aikawa⁴, Ana C Medeiros-Ribeiro³, Eduardo Borba¹, Emily Figueiredo Neves Yuki⁵, Artur Sartori², Danieli Andrade⁶, Thiago Freitas⁷, Henrique Giardini⁷, Clovis Artur Silva⁸ and Eloisa Bonfa¹, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁶University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: SLE patients are at increased risk of infections, including herpes zoster (HZ). Prior studies evaluating the recombinant herpes zoster vaccine (RZV) in SLE have…
Abstract Number: 0586 • ACR Convergence 2025
Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis
Siba Raychaudhuri¹, Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Mather, CA, ³Sacramento VA Medical Center, Davis, CA
Background/Purpose: Check point inhibitor PD-1 (programmed death protein 1) is upregulated during T lymphocyte activation and is important for limiting the duration of activation. Thus,…
Abstract Number: 0514 • ACR Convergence 2025
Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
Nicholas Bauer¹, Rufei Lu¹, Carla Guthridge¹, Tayte Stephens², Benjamin Jones³, Wade DeJager⁴, Susan Macwana¹, Caroline Shiboski⁵, Alan Baer⁶, Christopher Lessard¹, Astrid Rasmussen¹, Stephen Shiboski⁵, Judith James¹, Linda F. Thompson¹, Blake M. Warner⁷, A. Darise Farris¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma State University, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵University of California San Francisco, San Francisco, CA, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷National Institutes of Health, Bethesda, MD
Background/Purpose: Blood immunophenotyping reveals systemic immune alterations and therapeutically actionable molecular endotypes in Sjögren’s Disease (SjD). Reported changes include reduced memory B cells, plasmacytoid dendritic…
Abstract Number: 0630 • ACR Convergence 2025
Development, Validation and Performance of a Patient Knowledge Assessment Tool for Assessing the Immediate and Short-term Impact of an Information Course in Systemic Lupus Erythematosus
Ranjan Gupta, Rudra Prosad Goswami and Anju Mohan, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Long-term outcomes in rheumatic diseases can be improved by improving patients’ knowledge, beliefs and perception about their disease. However, there is a lack of…
Abstract Number: 0950 • ACR Convergence 2025
Ep300-Catalyzed Rad50 Lactylation Compromises Genomic Stability and Drives CD4+T cells Cell Senescence in SLE
mingyang zhang¹, huanzi dai², cun lan³ and mingyang sun³, ¹Daping Hospital, Army Medical University, chongqing, Chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic), ³Daping Hospital, Army Medical University, chongqing, China (People's Republic)
Background/Purpose: Senescent CD4+ T cells are increasingly implicated in systemic lupus erythematosus (SLE) pathogenesis. While metabolic reprogramming in lupus T cells enhances glycolysis and lactate…
Abstract Number: 1047 • ACR Convergence 2025
Primary Care Perspectives on Giant Cell Arteritis: Diagnostic Considerations, Referral Challenges, and Opportunities for Fast-Track Pathways in the U.S.
Ellen Ann Sockman¹, Jon Golenbiewski¹ and Rachel Wolfe², ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Wake Forest University School of Medicine, Winston-Salem
Background/Purpose: Giant Cell Arteritis (GCA) is a medical emergency that can lead to irreversible vision loss without prompt recognition and treatment. Primary care providers (PCPs)…
Abstract Number: 1034 • ACR Convergence 2025
Healthy Dietary Patterns and Risk of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Elena Joerns¹, Jeffrey Sparks², Cynthia Chelf¹, Cynthia Crowson³, John Davis¹ and Vanessa Kronzer¹, ¹Mayo Clinic, Rochester, MN, ²Brigham and Women's Hospital, Boston, MA, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Healthy dietary patterns are associated with many health benefits, including lower cardiovascular disease, mortality, and rheumatoid arthritis (RA) disease activity. Therefore, we aimed to…
Abstract Number: 0525 • ACR Convergence 2025
Cost-of-Illness Among Newly Diagnosed Patients with Psoriatic Arthritis in Sweden
Sofia Wittgren¹, Sofia Exarchou², Daniela Di Giuseppe³, Ulf Lindström⁴, Tor Olofsson¹, Lennart T. H. Jacobsson⁴, Johan Askling³ and Johan Karlsson Wallman¹, ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, ²Lund University, Åkarp, Skane Lan, Sweden, ³Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Stockholms Lan, Sweden, ⁴Gothenburg University, Sahlgrenska Academy, Department of Rheumatology and Inflammation Research, Gothenburg, Vastra Gotaland, Sweden
Background/Purpose: Up-to-date information on the cost-of-illness of psoriatic arthritis (PsA) is important for healthcare/social insurance system budgeting and to highlight unmet needs in PsA care.…
Abstract Number: 0048 • ACR Convergence 2025
Integrative Spatial Proteomics and Single-Cell RNA Sequencing Unveil Molecular Complexity in Rheumatoid Arthritis for Novel Therapeutic Targeting
Xue Wang¹, Fei Wang², Sílvia Sisó², Archana Iyer², Heather Knight², Lori Duggan², Yingli Yang², Liang Jin², Baoling Cui², Yupeng He³, Jan Schejbal², Lucy Phillips², Bohdan Harvey⁴ and Yu Tian², ¹AbbVie, South San Francisco, CA, ²AbbVie, Worcester, MA, ³AbbVie, North Chicago, IL, ⁴AbbVie, Cambridge, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation, fibroblast proliferation and progressive joint damage. Understanding the heterogeneity of RA and…
Abstract Number: 0959 • ACR Convergence 2025
Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
Bich Na Choi¹, Claudia Pedroza², Brian Skaug³, Maureen Mayes⁴ and Shervin Assassi⁵, ¹UTHealth Houston Institute for Clinical Research & Learning Health Care, Houston, TX, ²UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴UT Health Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX
Background/Purpose: Clinically useful biomarkers for systemic sclerosis (SSc) are needed. While obtaining samples from affected organs like the skin and lungs is invasive and cannot…
Abstract Number: 1066 • ACR Convergence 2025
Assessing Disparities in Outcomes and Processes of Care for Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Jon Burnham⁴, Cagri Yildirim-Toruner⁵, Tzielan Lee⁶, Kerry Ferraro⁷, Erik Friedrichsen⁸, Katelyn Banschbach⁹, Michelle Batthish¹⁰, Danielle Fair¹¹, Mileka Gilbert¹², Beth Gottlieb¹³, Melissa Mannion¹⁴, Edward Oberle¹⁵, Nancy Pan¹⁶, Natalie Rosenwasser¹⁷, Mary Toth¹⁸, Jennifer Weiss¹⁹ and Esi Morgan¹⁷, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children's Hospital, Hershey, PA, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁵Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Seattle Children's Hospital, Burien, WA, ⁹cincinnati Children's hospital, Villa Hills, KY, ¹⁰McMaster Children's Hospital, Hamilton, ON, Canada, ¹¹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ¹²Medical University of South Carolina, Charleston, SC, ¹³Cohen Children's Medical Center, Northwell Health, Lake Success, NY, ¹⁴University of Alabama at Birmingham, Birmingham, AL, ¹⁵Nationwide Children's Hospital, Columbus, OH, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷Seattle Children's Hospital, seattle, WA, ¹⁸Nemours Foundation, Orlando, FL, ¹⁹Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) has a mission to deliver exceptional and equitable health care to children with rheumatic diseases…
Abstract Number: 0030 • ACR Convergence 2025
Immune-related Diagnoses Associated with NOD2 Variants in Human Subjects: A Phenome-wide Association Study
John Davis¹, Elizabeth Atkinson¹, Vanessa Kronzer¹, Cynthia Crowson², Afsaneh Alavi³, John Damianos¹, Loftus Edward¹, Joseph Murray¹, Ann Moyer¹ and Filippo Pinto e Vairo¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Stewartvillle, MN, ³Department of Dermatology, Mayo Clinic, Rochester, MN
Background/Purpose: The nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene is associated with risk for several inflammatory diseases, including Crohn disease, Blau syndrome, and Yao syndrome…
Abstract Number: 0650 • ACR Convergence 2025
Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Brad Rovin¹, Jay Garg², Richard Furie³, Rachel Jones⁴, Amit Saxena⁵, Pasquale Esposito⁶, Elsa Martins⁷, Claire Petry⁷, Nicolas Frey⁷, Bongin Yoo², Imran Hassan⁸, Thomas Schindler⁷, Theodore Omachi⁹, William Pendergraft², Mittermayer Santiago¹⁰, Gustavo Aroca Martínez¹¹ and Ana Malvar¹², ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁶Clinica Nefrologica, Dialisi, Trapianto, Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁹Genentech, Inc., South San Francisco, ¹⁰Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Bahia, Brazil, ¹¹Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ¹²Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when…
Abstract Number: 1036 • ACR Convergence 2025
Factors Associated With Long-term Remission After Drug Discontinuation In IgG4-related Disease: A 3-Year Rule
Yifei Wang¹, Yuxue Nie², Jingna Li³, Jialei Zhang⁴, Qinhuan Luo¹, Xinli Yang⁵, Jialing Jiang¹, Nianyi Zhang⁶, Linyi Peng⁷, Yunyun Fei⁶, Jiaxin zhou⁴ and Wen Zhang⁸, ¹Peking Union Medical College, Beijing, China (People's Republic), ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, Dong Cheng Qu, China (People's Republic), ³Peking Union Medical College, Dong Cheng Qu, Beijing, China, ⁴Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁵Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷PEKING UNION MEDICAL COLLEGE HOSPITAL, Beijing, Beijing, China, ⁸Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic)
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder with multi-organ involvement and elevated serum IgG4 levels. Glucocorticoids (GC) with or without immunosuppressants (IM) are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].